Trial Profile
Safety and Patient Satisfaction With GLASH VISTA (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary)
- Indications Hypotrichosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allergan
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.
- 24 Jul 2017 Planned End Date changed from 1 Jun 2018 to 8 Jun 2018.
- 24 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 8 Jun 2018.